MiniMed 780G Sustains 80.6% Time in Range and 6.8% HbA1c with Two Sensors
MiniMed 780G users in a randomized crossover study maintained Time in Range of 80.6% with Simplera Sync and 79.1% with Instinct sensors and HbA1c of 6.8% vs 6.7%, highlighting its SmartGuard algorithm’s control. A real-world analysis of over 20,000 users confirmed consistent Time in Range above 76% across sensors.
1. Study Design and Methodology
The randomized crossover trial enrolled 24 adults with type 1 diabetes who used the MiniMed 780G system with either the Simplera Sync or Instinct sensor for six weeks before switching to the alternate sensor for another six weeks. Each period employed a new insulin pump to eliminate algorithm memory effects and isolate sensor performance.
2. Key Glycemic Metrics
Participants achieved a Time in Range of 80.6% with Simplera Sync versus 79.1% with Instinct, HbA1c levels of 6.8% and 6.7% respectively, mean sensor glucose readings of 139.5 mg/dL versus 137.9 mg/dL, and spent over 90% of time in auto mode on both sensors.
3. Real-World Evidence
An analysis of more than 20,000 U.S. users transitioning between sensors showed Time in Range improvements from 74.8% to 76.6% with recommended settings and up to 80.5% for Instinct users, alongside stable glycemic management metrics across the broader user base.
4. Strategic Implications
Demonstrating virtually identical outcomes across two sensor brands underscores the SmartGuard algorithm as the primary driver of insulin delivery performance, supporting flexible sensor adoption and strengthening MiniMed’s competitive positioning in automated insulin delivery.